For the Quarter Ending December 2025
North America
• In the USA, the Carbidopa Price Index rose by 1.96% quarter-over-quarter, supported by pharmaceutical procurement.
• The average Carbidopa price for the quarter was approximately USD 275658.33/MT, following measured replenishment activity.
• Carbidopa Spot Price remained firm as import allocations prioritized contract manufacturers fulfilling year-end formulations volumes.
• Carbidopa Price Forecast anticipates mild upward momentum driven by steady offtake and constrained domestic volumes.
• Carbidopa Production Cost Trend remained neutral as materials traded sideways while QA expenses slightly increased.
• Carbidopa Demand Outlook remained predictable with hospital and pharmacy replenishment maintaining steady API purchase patterns.
• Carbidopa Price Index movements were moderated by lower freight pass-through and contractual fixed-rate shipping arrangements.
• Inventory at West Coast warehouses stayed lean, prompting measured purchasing that modestly supported CFR offers.
Why did the price of Carbidopa change in December 2025 in North America?
• Steady offtake from Parkinsons therapy manufacturers maintained procurement, supporting modest upward pressure despite logistical improvements.
• Lower container freight reduced transport costs, but fixed annual contracts limited landed-price pass-through to buyers.
• Regulatory compliance and QA expenses at some exporters added landed cost premia, keeping prices elevated.
APAC
• In China, the Carbidopa Price Index rose by 1.96% quarter-over-quarter, supported by firm export demand.
• The average Carbidopa price for the quarter was approximately USD 275563.33/MT, reflecting steady export bookings globally.
• Exporters reported Carbidopa Spot Price remained firm as Latin American and Indian buyers increased procurement.
• Carbidopa Price Forecast indicates modest upside as exporters expect orderly orders and limited spot availability.
• Carbidopa Production Cost Trend stayed subdued due to stable feedstock and unchanged solvent prices globally.
• Carbidopa Demand Outlook remains steady, driven by Parkinsons programmes and disciplined procurement from formulators domestically.
• Moderate-to-low inventories and firm export bookings supported the Carbidopa Price Index, limiting scope for declines.
• Major API plant operations remained routine with no enforcement disruptions, keeping outbound flows reliably steady.
Why did the price of Carbidopa change in December 2025 in APAC?
• Export demand from Brazil and India absorbed volumes, offsetting domestic procurement caps and supporting prices.
• Stable feedstock availability and unchanged solvent costs kept production economics steady, limiting upward cost pressure.
• Port operations and freight avoided logistics premiums, encouraging adherence to contracted allocations rather than re-scheduling.
Europe
• In Germany, the Carbidopa Price Index rose by 1.95% quarter-over-quarter, reflecting measured procurement and steady imports.
• The average Carbidopa price for the quarter was approximately USD 275638.33/MT, reflecting steady contracted procurement patterns.
• Carbidopa Spot Price movements stayed narrow as balanced imports and routine production limited volatility in the Price Index.
• Carbidopa Price Forecast indicates modest upward bias driven by predictable offtake and disciplined importer ordering into Q1.
• Carbidopa Production Cost Trend showed limited pass-through as feedstock and freight movements remained largely stable during December.
• Carbidopa Demand Outlook remains steady with contract manufacturers maintaining regular API pulls for Parkinsons therapies through year-end.
• Carbidopa Price Index rose slightly as moderate inventories and uninterrupted exports kept supply-demand balance tight without sharp spikes.
• Major producers operated planned campaigns; German domestic output remained subdued due to high electricity tariffs and limited local availability.
Why did the price of Carbidopa change in December 2025 in Europe?
• Balanced import volumes and scheduled API campaigns prevented acute shortages, limiting upward price pressure effectively.
• Stable freight and port operations removed logistical premiums, restraining cost pass-through into the Carbidopa Price Index.
• Predictable pharmaceutical demand and conservative inventory rebuilds kept buying measured, supporting only marginal index increases.
For the Quarter Ending September 2025
North America
• In USA, the Carbidopa Price Index rose by 0.34% quarter-over-quarter, reflecting modest imbalances from stockpile adjustments.
• The average Carbidopa price for the quarter was approximately USD 270350/MT, representing distributor-level weighted average.
• Carbidopa Spot Price eased in August as logistics costs normalized and inventory overhang reduced urgent purchasing pressures.
• Carbidopa Price Forecast indicates gradual recovery supported by restocking, yet constrained by trade policy uncertainty and inflation.
• Carbidopa Production Cost Trend shows limited upward pressure from freight and handling, while feedstock costs remain benign.
• Carbidopa Demand Outlook remains subdued into September as buyers prioritize inventory normalization over speculative replenishment amid policy risk.
• Carbidopa Price Index volatility reflected short-term congestion relief, restocking waves, and cautious distributor margin restoration measures.
• Inventory buffers expanded after June stockpiling, reducing immediate import urgency and tempering spot bids across US distribution channels.
Why did the price of Carbidopa change in September 2025 in North America?
• Reduced import volumes after pre-season stockpiling eased supply tightness, prompting sellers to lower bid levels.
• Normalized freight rates and eased port congestion decreased landed costs, enabling suppliers to offer more competitive pricing.
• Cautious buyer behavior and inventory normalization suppressed demand, increasing pressure on spot trades and transactional volumes.
APAC
• In China, the Carbidopa Price Index rose by 0.35% quarter-over-quarter during 2025, reflecting demand weakness.
• The average Carbidopa price for the quarter was approximately USD 270253.33/MT from exporters/formulators.
• Carbidopa Spot Price softened as inventories accumulated, pressuring exporters to offer volumes and lead times.
• Carbidopa Price Forecast indicates modest gains ahead, driven by selective restocking and gradual inventory normalization.
• Carbidopa Production Cost Trend showed reduced logistics and input pressures but weather-related cost spikes persisted.
• Carbidopa Demand Outlook remains cautious with Western buyers deferring purchases, limiting sustained upward price momentum.
• Carbidopa Price Index volatility was influenced by declining freight costs and typhoon-related port delays persisting.
• Producers adjusted output schedules; smaller exporters may consolidate as margins tightened, moderating near-term market recovery.
Why did the price of Carbidopa change in Sep 2025 in APAC?
• Oversupply and accumulated inventories pressured sellers, prompting discounting to stimulate offtake during September shipment period.
• Lower spot container freight rates reduced exporter cost pressure, giving buyers leverage in price negotiations.
• Muted international demand and purchasing strategies led buyers to defer orders, limiting price recovery momentum.
Europe
• In Germany, the Carbidopa Price Index rose by 0.3563% quarter-over-quarter, reflecting elevated inventories and soft demand.
• The average Carbidopa price for the quarter was approximately USD 270356.67/MT, based on CFR Hamburg transactions.
• Carbidopa Spot Price softened as distributors liquidated older stock, keeping the Carbidopa Price Index subdued.
• Carbidopa Price Forecast anticipates recovery as postponed PSS activations and restocking drive higher import costs.
• Carbidopa Production Cost Trend showed upward pressure from freight surcharges and logistics inefficiencies, elevating landed costs.
• Carbidopa Demand Outlook remains cautious, with healthcare buyers prioritizing inventory optimization over aggressive purchasing this quarter.
• High inventory buffers and steady exports constrained price rallies, keeping the Carbidopa Price Index largely rangebound.
• Selective restocking followed port congestion easing, with producers maintaining regular operations and availability to markets.
Why did the price of Carbidopa change in September 2025 in Europe?
• Elevated inventories and subdued purchasing reduced immediate spot demand, applying downward pressure on local pricing.
• Postponed PSS activations plus port congestion increased uncertainty and freight costs, prompting cautious buying decisions.
• Import timing shifts and delayed shipments tightened short-term availability intermittently, supporting selective price recoveries periodically.
For the Quarter Ending June 2025
North America
• The Price Index for Carbidopa USP CFR Los Angeles fell from USD 268,100/MT in April to USD 268,990/MT in June, despite a peak in May, reflecting overall Q2 volatility with a net drop of 0.81%.
• In April, strategic frontloading ahead of tariff hikes and sufficient inventory levels reduced buying activity, pushing the carbidopa spot price downward as suppliers absorbed part of tariff costs.
• The product demand outlook in April was weak, with downstream buyers delaying purchases and minimizing restocking due to ample inventories and tariff-related caution.
• In May, the temporary 90-day suspension of Chinese pharmaceutical tariffs led to a rush of imports, pushing carbidopa prices up by 1.16% due to port congestion and high global freight costs.
• Strong May procurement activity, driven by General Rate Increase (GRI) expectations and mild U.S. inflation, boosted the product demand outlook and short-term prices.
• June saw a reversal, as freight corrections, excess inventory, and weak consumer sentiment caused the price index to drop again by 0.81%.
• Slowing booking activity in June and ongoing destocking by pharmaceutical hubs indicate a declining product price forecast entering Q3.
• With ocean freight spot rates softening and distributors liquidating stock, carbidopa production cost trend eased slightly in late June.
• Domestic demand in June remained soft as buyers waited for tariff clarity and Q2 close financial cycles reduced procurement.
• In July 2025, carbidopa prices are likely to increase modestly, as suppliers shift focus from liquidation to margin recovery, and localized supply tightness emerges due to cautious restocking.
APAC
• The Carbidopa USP FOB Shanghai Price Index declined by 0.85% in June to USD 268,800/MT, after a brief rebound in May; April had started at a lower Price Index of USD 268,000/MT, reflecting high volatility during Q2.
• In April, the Price Index fell 1.40% due to inventory overhang, disrupted logistics, and weak overseas buying. carbidopa spot price was pressured by reduced factory activity and ongoing port congestion, limiting distribution capacity despite sufficient supply.
• The enforcement of 145% U.S. tariffs on Chinese pharmaceutical goods led to foreign order cancellations, sharply eroding the carbidopa demand outlook and forcing suppliers to offer steep discounts to move excess stock.
• May marked a Price Index recovery of 1.16%, spurred by a 90-day U.S. tariff reprieve that triggered frontloaded international procurement. Buyers rushed to secure inventory amid rising freight costs and limited shipping availability.
• Carbidopa production cost trend rose temporarily in May as spot container rates surged by 27% due to booking congestion from U.S. importers trying to beat tariff reinstatement deadlines.
• Peak Season Surcharges (PSS) and General Rate Increases (GRIs) announced for early June prompted aggressive booking, improving inventory turnover and driving up the carbidopa spot price during the month’s first half.
• However, the Price Index dipped again in June, reversing prior gains. Overcapacity and a 3.6% YoY fall in China's Producer Price Index (PPI) reduced input costs, signaling a downtrend in carbidopa production cost trend.
• Global buyers adopted a cautious “wait and see” strategy in June due to weak short-term demand and adequate stock levels. This further weakened the carbidopa demand outlook, with many deferring purchases.
• Domestic consumption in China remained subdued in Q2, as formulators showed restraint amid economic uncertainty and limited stimulus, adding further strain on the carbidopa spot price.
• July 2025 suggests that mild increase is likely due to short-term international stock replenishment after June’s price dip. However, lingering inventory pressures and stable production may cap gains as sellers realign output schedules cautiously.
Europe
• April 2025 saw the Price Index for Carbidopa USP in Germany fall by 1.39%, reaching a Spot Price of USD 268,090/MT, driven by a supply glut as US-bound cargoes were diverted to Europe due to tariffs.
• Subdued carbidopa demand outlook across pharmaceutical sectors, coupled with heavy pre-stocking ahead of Labour Day, flooded the German market with inventories, further depressing prices.
• Steady imports from Asia and robust vessel availability sustained an oversupplied market throughout April, keeping landed costs low and restricting any upward momentum in the price forecast.
• In May 2025, the Price Index rose by 1.16% to USD 271,190/MT, amid rising freight congestion, space constraints, and a surge in forward bookings driven by anticipated GRIs and recovering demand outlook.
• Port disruptions at Hamburg and Bremerhaven severely limited shipment flow, enabling sellers to raise prices due to reduced production cost trend pressures and inventory gaps.
• The easing of US tariffs mid-May prompted vessel reallocation, tightening space on Asia–Europe routes and amplifying price gains in Germany.
• June 2025 saw prices edge down 0.84% to USD 268,910/MT as cautious buyers paused procurement and sellers offloaded excess stocks before quarter-end.
• Postponement of PSS by carriers reduced urgency in purchasing decisions, softening the carbidopa spot price trajectory and creating a flat price forecast for early Q3.
• Demand outlook in June was tepid due to adequate inventories, limiting new trade activity amid ongoing logistical constraints.
• For July 2025, the Price Index is likely to increase as downstream industries begin restocking and PSS activations raise import landed costs across Germany.
For the Quarter Ending March 2025
North America
Carbidopa prices in the U.S. experienced mixed movements in Q1 2025, influenced by trade policies, supply dynamics, and shifting demand. January saw a moderate price increase as importers accelerated shipments ahead of a proposed 10% tariff on Chinese goods. This surge in buying, coupled with the Chinese Lunar New Year and elevated energy costs, strained supply chains and drove prices upward.
However, in February, prices declined as post-holiday manufacturing recovery in China boosted supply and transpacific shipping rates dropped due to excess capacity. At the same time, demand softened amid economic uncertainty, stockpiled inventories, and cautious buyer sentiment related to potential new tariffs on Indian pharmaceuticals.
In March, prices edged up again as buyers resumed procurement in anticipation of broader tariff measures introduced by former President Trump on March 4. Stabilized supply and improved consumer sentiment, driven by easing inflation, further supported this uptick.
Overall, Q1 was marked by tariff-driven volatility, fluctuating demand, and trade-related stockpiling, creating a dynamic pricing environment for Carbidopa in the U.S. market.
Asia Pacific
Carbidopa prices in China exhibited a fluctuating trend during Q1 2025, driven by shifting supply-demand dynamics and trade developments. In January, prices rose slightly as pharmaceutical demand strengthened and manufacturers faced seasonal production slowdowns ahead of the Lunar New Year. Distributors frontloaded orders in response to potential U.S. tariffs, tightening supply and boosting prices. However, February saw a slight decline as production normalized post-holiday, leading to stable supply and higher inventories. Weak domestic consumption, deflationary sentiment, and sluggish demand from Western markets further weighed on prices. By March, Carbidopa prices increased notably due to strong domestic and foreign demand outpacing supply recovery. Low starting inventories, restocking activity, and anticipation of plant maintenance contributed to tighter availability. Foreign buyers also rushed procurement ahead of potential trade restrictions, reinforcing bullish sentiment. Overall, Q1 was marked by volatility: early price gains from export urgency and seasonal disruptions, mid-quarter weakness from soft demand, and a strong rebound in March as supply lagged behind recovering demand.
Europe
In Q1 2025, Carbidopa prices in Germany displayed a fluctuating trend shaped by dynamic shifts in sentiment, supply conditions, and procurement behavior. January saw a moderate price rise as improved business morale and favorable monetary conditions boosted demand from healthcare and pharmaceutical sectors. Buyers accelerated inventory restocking amid early Lunar New Year-driven shipments and Red Sea diversions, contributing to upward price pressure. However, February brought a reversal, with prices declining due to subdued demand and abundant supply. Early stockpiling, weak consumer confidence, and political uncertainties ahead of elections curbed downstream purchases. Concurrently, the appreciated Euro and a significant drop in freight rates enabled cost-efficient imports, further pressuring prices. By March, prices rebounded due to tighter supply caused by European port congestion and labor unrest. Restocking resumed, aided by firmer pharmaceutical sector sentiment and a slight easing in Eurozone inflation, prompting more assertive purchasing. This shift allowed suppliers to raise price offers, supported by recovering demand and logistical challenges. Overall, Q1 was marked by alternating supply-demand dynamics, with inventory strategies and macroeconomic sentiment playing pivotal roles in shaping Carbidopa’s price trajectory.
